Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cystectomy Clear all
Completed Not applicable Interventional Results available

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery

NCT02073162
View directory record Official record
Conditions
Major Abdominal Surgery
Interventions
Major Abdominal Surgery
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 2, 2026, 4:05 PM EDT
Completed No phase listed Observational

Study of Outcomes After Surgery/Treatment to Treat Bladder Cancer

NCT01776138
View directory record Official record
Conditions
Bladder Cancer
Interventions
Collect Blood and Survey Instruments
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Sep 2, 2026, 4:05 PM EDT
Recruiting No phase listed Observational

Discharge Medication Use Post-Operatively in GU Cancer Patients

NCT06795087
View directory record Official record
Conditions
Genitourinary Cancer
Interventions
Opioid Medication Disposal Education
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 2, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy

NCT03319745
View directory record Official record
Conditions
Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8
Interventions
Pembrolizumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 2, 2026, 4:05 PM EDT
Terminated Not applicable Interventional Results available

Radical Cystectomy: Can We Improve Our Surgical Technique With the Ligasure Impact Tissue-Sealing Device?

NCT00802633
View directory record Official record
Conditions
Bladder Cancer, Hemostasis
Interventions
Stapling device during radical cystectomy, Ligasure tissue sealing device
Device
Lead sponsor
Vanderbilt University
Other
Eligibility
19 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 2, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer

NCT00055601
View directory record Official record
Conditions
Bladder Cancer
Interventions
cisplatin, fluorouracil, paclitaxel, radiation therapy, Gemcitabine, Radical cystectomy
Drug · Radiation · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Up to 120 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2018
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 2, 2026, 4:05 PM EDT
Active, not recruiting Phase 2 Interventional

Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer

NCT04289779
View directory record Official record
Conditions
Bladder Cancer
Interventions
Cabozantinib, Atezolizumab, Cystectomy
Drug · Procedure
Lead sponsor
Deepak Kilari
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
St Louis, Missouri • Hackensack, New Jersey • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 2, 2026, 4:05 PM EDT
Recruiting Phase 2 Interventional

Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy

NCT06184516
View directory record Official record
Conditions
Urothelial Carcinoma Bladder
Interventions
Reproductive organ sparing radical cystectomy, Radical cystectomy
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 2, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

NCT04383743
View directory record Official record
Conditions
Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma
Interventions
Cisplatin, Doxorubicin, Methotrexate, Pegfilgrastim, Pembrolizumab, Radical Cystectomy, Vinblastine Sulfate
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 2, 2026, 4:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy

NCT02355886
View directory record Official record
Conditions
Bladder Carcinoma
Interventions
Gabapentin, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 2, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC

NCT00859339
View directory record Official record
Conditions
Transitional Cell Carcinoma of the Bladder
Interventions
Gemcitabine, Cisplatin, Sunitinib Malate, Radical Cystectomy
Drug · Procedure
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Gainesville, Florida • Indianapolis, Indiana • South Bend, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 2, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Thoracic Epidural Analgesia Versus Rectus Sheath Block Versus Surgeon Infiltration With Liposomal Bupivacaine or Standard Bupivacaine for Post-Operative Pain Control After Cystectomy

NCT04300231
View directory record Official record
Conditions
Cystectomy
Interventions
epidural bupivacaine 0.05%, Liposomal bupivacaine, bupivacaine 0.125%, bupivacaine 0.5%, /hydromorphone 0.05mg/ml, injectable saline
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 2, 2026, 4:05 PM EDT
Completed Phase 3 Interventional

A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy

NCT02145871
View directory record Official record
Conditions
Bladder Cancer
Interventions
standard fluid management, fluid management guided by the EV1000
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 2, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

NCT03404791
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
TAR-200
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
9
States / cities
Phoenix, Arizona • Dalton, Georgia • Hanover, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 2, 2026, 4:05 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

NCT03520491
View directory record Official record
Conditions
Bladder Cancer
Interventions
Nivolumab, Ipilimumab, Radical cystectomy
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 2, 2026, 4:05 PM EDT
Recruiting Not applicable Interventional

Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

NCT07234968
View directory record Official record
Conditions
Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma, Pelvic Malignancy, Bladder Transitional Cell Carcinoma, Bladder Neoplasm
Interventions
Ureteral Stent Placement, No Ureteral Stent, Indocyanine Green with Fluorescence Imaging
Procedure · Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 2, 2026, 4:05 PM EDT
Completed Not applicable Interventional Results available

Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

NCT01157676
View directory record Official record
Conditions
Bladder Cancer Requiring Cystectomy
Interventions
Open radical cystectomy, Robotic assisted radical cystectomy, DaVinci robot
Procedure · Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
16
States / cities
Phoenix, Arizona • Orange, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 2, 2026, 4:05 PM EDT
Completed Early Phase 1 Interventional

Impact Advanced Recovery® for Radical Cystectomy (RC) Patients: a Pilot Study

NCT01868087
View directory record Official record
Conditions
Bladder Cancer, Radical Cystectomy, Urinary Bladder Neoplasms, Surgery
Interventions
Boost Plus®, Impact Advanced Recovery®
Dietary Supplement
Lead sponsor
Jill Hamilton-Reeves, PhD RD LD
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 2, 2026, 4:05 PM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

NCT05241340
View directory record Official record
Conditions
Urothelial Carcinoma Bladder
Interventions
Sasanlimab, Stereotactic Body Radiation Therapy, Radical Cystectomy + pelvic lymph node dissection + urinary diversion
Drug · Radiation · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 2, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer

NCT01824329
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Interventions
Prostate capsule sparing cystectomy, Nerve sparing cystectomy
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Sep 2, 2026, 4:05 PM EDT
Terminated Phase 3 Interventional Results available

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

NCT04197986
View directory record Official record
Conditions
Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
Interventions
Infigratinib, Placebo
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
47
States / cities
Tucson, Arizona • Duarte, California • Loma Linda, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 2, 2026, 4:05 PM EDT
Recruiting Not applicable Interventional

Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy

NCT05792722
View directory record Official record
Conditions
Bladder Cancer
Interventions
Prostate capsule-sparing radical cystectomy, Nerve sparing radical cystectomy
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 2, 2026, 4:05 PM EDT
Terminated Not applicable Interventional

Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer

NCT02699853
View directory record Official record
Conditions
Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
Interventions
Questionnaire Administration, Radical Cystectomy
Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Sep 2, 2026, 4:05 PM EDT
Active, not recruiting Early Phase 1 Interventional

(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer

NCT03837821
View directory record Official record
Conditions
Bladder Cancer
Interventions
Abemaciclib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 2, 2026, 4:05 PM EDT